Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neoplasms With Mesothelin Expression”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Early research (Phase 1)Study completedNCT04034238
What this trial is testing

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Who this might be right for
Neoplasms With Mesothelin ExpressionEpithelioid MesotheliomaCholangiocarcinoma, Extrahepatic+1 more
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Looking for participantsNCT06051695
What this trial is testing

Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNSCLC+17 more
A2 Biotherapeutics Inc. 474
Early research (Phase 1)Looking for participantsNCT07030907
What this trial is testing

Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer RecurrentOvarian CancerPlatinum Resistant Ovarian Cancer
Outpace Bio, Inc. 30
Early research (Phase 1)Study completedNCT04727554
What this trial is testing

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Amgen 11
Early research (Phase 1)Looking for participantsNCT06756035
What this trial is testing

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Who this might be right for
Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, Advanced+8 more
Context Therapeutics Inc. 70
Early research (Phase 1)Study completedNCT03872206
What this trial is testing

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

Who this might be right for
Advanced Cancers Associated With Mesothelin Expression
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 95